SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Risk Assessment
On Oct. 15, 2026, SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today…